ChiCTR2600115926
尚未开始
/
/
/
2026-01-04
/
/
Central Obesity
An innovative approach to combine intermittent dieting (INTD) with high-intensity interval exercise (HIIE) for curbing central obesity: A comparative randomized controlled trial
An innovative approach to combine intermittent dieting (INTD) with high-intensity interval exercise (HIIE) for curbing central obesity: A comparative randomized controlled trial
The proposed study aims to investigate the effects of high-intensity interval exercise (HIIE) and an intermittent diet (INTD) separately and their combined effects in physically inactive adults with central obesity.
随机平行对照
其它
Participants will be randomised by an independent research assistant using a computer-based random number generator.
Participants were not informed of the specific hypothesis of the study, but due to the nature of the intervention, participants and instructors cannot be blinded. The assessors will be blinded to the group allocation during the evaluation of the indicators before, during, and after the intervention.
Health and Medical Research Fund
/
25
/
2026-01-05
2026-12-31
/
The target population of the proposed study will be physically inactive middle-aged adults (aged 40–64 years) with central obesity in Hong Kong. This particular age group is chosen as the prevalence of central obesity generally increased with age according to the Population Health Survey 2020-22 (2). Physical inactivity will be defined as having less than 3 days of 30-minute moderate-intensity physical activity per week and will be objectively assessed using a device-based measure (i.e. activPAL accelerometer) (3). Central obesity is defined as having a waist circumference 90 centimeters (cm) or above for men and 80 cm or above for women (2). Furthermore, a waist-to-hip ratio at 0.90 or above for men and 0.85 for women also signify centrally obese.；
请登录查看Participants who are not centrally obese will be excluded.；
请登录查看The Chinese University of Hong Kong
/
GLP1减重宝典2026-01-10
良医汇肿瘤资讯2026-01-10
易慕峰2026-01-10
医药笔记2026-01-10
信立泰药业2026-01-10
Medactive2026-01-10
兽药资讯2026-01-10
药时空2026-01-10
德睿智药2026-01-10
丁香园 Insight 数据库2026-01-10
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
